HIV Malignancy Specimens for Research at No Charge
Kudos to Dr. Rebecca Liddell Huppi, the ACSR’s NCI Partner, on the NCI Global Health tweet which featured her quote about the significance of global health. To learn more about …
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- …
The National Cancer Institute (NCI) and Cancer Research UK (CRUK), the world’s leading funders of cancer research, are partnering to fund the Cancer Grand Challenges (CGC) program. Cancer Grand Challenges …
FOA Number: RFA-CA-20-046 Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance …
POZ “Viral Control” Q & A with Dr. Robert Yarchoan, Director of the Office of HIV and AIDS Malignancy at the U.S. National Cancer Institute. (READ MORE)
This meeting is presented by the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services will take place October …
The fellowship program was established to encourage and foster the development of new and junior clinical investigators at our domestic and international sites to pursue careers in clinical research trials …
For more information about this potential funding opportunity, please check out the Office of HIV and AIDS Malignancy’s presentation of the FOA Concept to the Board of Scientific Advisors on …
This meeting is presented by the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services will take place October …
The HIV and AIDS Malignancy Branch (HAMB) is seeking a tenure-eligible or tenure-track investigator in the field of HIV–related malignancies or viral oncogenesis. (READ MORE)